Results 11 to 20 of about 8,272 (178)

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach. [PDF]

J Adv Pract Oncol, 2019
Systemic immunoglobulin light-chain (AL) amyloidosis is a rare disorder arising from a plasma cell clone that produces misfolded immunoglobulin light chains, which are deposited in various tissues and organs as amyloid fibrils. Signs and symptoms are typically vague and overlap with those arising from other common diseases; consequently, diagnosis of ...
Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, Mendelson L.   +6 more
europepmc   +4 more sources

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. [PDF]

Blood Cancer J, 2018
AbstractImmunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea.
Gertz MA.
europepmc   +4 more sources

Immunoglobulin light chain amyloidosis [PDF]

memo - Magazine of European Medical Oncology, 2021
SummaryImmunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains. The monoclonal light chain paraprotein originates from a small clonal B‑cell or a clonal plasma cell population.
Hermine Agis, Maria T. Krauth
openaire   +1 more source

Systemic immunoglobulin light chain amyloidosis [PDF]

Nature Reviews Disease Primers, 2018
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the conversion of immunoglobulin light chains from their soluble functional states into highly organized amyloid fibrillar aggregates that lead to organ dysfunction.
Merlini G., Dispenzieri A., Sanchorawala V., Schonland S. O., Palladini G., Hawkins P. N., Gertz M. A.   +6 more
openaire   +6 more sources

Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting. [PDF]

J Hematol Oncol
Bu Q, Zhu HH, Chen W.
europepmc   +2 more sources

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. [PDF]

Circ Heart Fail, 2022
Maurer MS, Dunnmon P, Fontana M, Quarta CC, Prasad K, Witteles RM, Rapezzi C, Signorovitch J, Lousada I, Merlini G.   +9 more
europepmc   +2 more sources

The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. [PDF]

Amyloid, 2020
Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A.   +3 more
europepmc   +2 more sources

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

Hemato, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Shayna Sarosiek, Andrew R. Branagan, Steven P. Treon, Jorge J. Castillo   +3 more
doaj   +1 more source

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source